Business Context and Reporting Period
This Form 6-K filing by Embraer S.A. covers the period ending June 30, 2017. The report details a strategic commercial announcement made on June 20, 2017, at the 52nd International Paris Air Show regarding a new aircraft order and service agreement with Fuji Dream Airlines (FDA).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The only specific financial value disclosed relates to the new order:
- Total Potential Order Value: USD 274 million (based on 2017 list prices if all purchase rights are exercised).
- Firm Order: 3 E175 aircraft.
- Purchase Rights: 3 additional E175 aircraft.
Material Changes
The primary material change reported is the addition of the firm order for three E175 aircraft to Embraer's 2017 second-quarter backlog. Additionally, FDA extended its Flight Hour Program (Pool) agreement with Embraer for up to eight years, covering the existing and new fleet.
Outlook, Commentary, and Risks
Management Commentary: John Slattery, President & CEO of Embraer Commercial Aviation, emphasized the strong eight-year partnership with FDA and the aircraft's role in the airline's network expansion and fuel efficiency. Yohei Suzuki, CEO of FDA, highlighted the reliability and performance of the E-Jets in supporting profitable growth.
Operational Details: The new E175s will feature an 84-seat single-class layout and the Autoland system for CAT III approaches. FDA currently operates 11 aircraft (three E170s and eight E175s) and achieved a 99.87% schedule reliability in 2016.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies. The total order value is contingent upon the exercise of purchase rights for the additional three aircraft.
Investor Verification Checklist
- Verify the inclusion of the three firm E175 orders in Embraer's official Q2 2017 backlog figures in subsequent earnings reports.
- Monitor the exercise status of the three purchase rights for additional E175s to confirm if the full USD 274 million potential value is realized.
- Review the terms of the extended Flight Hour Program (Pool) to understand the long-term service revenue implications.
- Confirm FDA's delivery schedule for the new aircraft to assess future revenue recognition timing.